HomeCompareBIOVF vs VIG

BIOVF vs VIG: Dividend Comparison 2026

BIOVF yields 5.02% · VIG yields 1.61%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VIG wins by $4.5K in total portfolio value
10 years
BIOVF
BIOVF
● Live price
5.02%
Share price
$39.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$691.40
Full BIOVF calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.61%
Share price
$215.06
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.3K
Annual income
$175.21
Full VIG calculator →

Portfolio growth — BIOVF vs VIG

📍 VIG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIOVFVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIOVF + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIOVF pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOVF
Annual income on $10K today (after 15% tax)
$426.38/yr
After 10yr DRIP, annual income (after tax)
$587.69/yr
VIG
Annual income on $10K today (after 15% tax)
$136.50/yr
After 10yr DRIP, annual income (after tax)
$148.93/yr
At 15% tax rate, BIOVF beats the other by $438.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOVF + VIG for your $10,000?

BIOVF: 50%VIG: 50%
100% VIG50/50100% BIOVF
Portfolio after 10yr
$30.0K
Annual income
$433.30/yr
Blended yield
1.44%
📊

Analyst Conviction Gap

Where Wall Street is split right now

BIOVF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
3.7
Piotroski
6/9
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOVF buys
0
VIG buys
0
No recent congressional trades found for BIOVF or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIOVFVIG
Forward yield5.02%1.61%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$27.8K$32.3K
Annual income after 10y$691.40$175.21
Total dividends collected$6.0K$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BIOVF vs VIG ($10,000, DRIP)

YearBIOVF PortfolioBIOVF Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$11,202$501.63$11,301$160.59$99.00VIG
2$12,511$525.15$12,752$162.91$241.00VIG
3$13,935$548.15$14,370$165.02$435.00VIG
4$15,481$570.60$16,176$166.93$695.00VIG
5$17,157$592.44$18,188$168.67$1.0KVIG
6$18,972$613.63$20,432$170.25$1.5KVIG
7$20,934$634.14$22,933$171.68$2.0KVIG
8$23,053$653.95$25,720$172.98$2.7KVIG
9$25,340$673.04$28,827$174.15$3.5KVIG
10$27,805$691.40$32,288$175.21$4.5KVIG

BIOVF vs VIG: Complete Analysis 2026

BIOVFStock

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Full BIOVF Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this BIOVF vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOVF vs SCHDBIOVF vs JEPIBIOVF vs OBIOVF vs KOBIOVF vs MAINBIOVF vs DGROBIOVF vs NOBLBIOVF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.